Published UCLA and Spectrum Saliva Liquid Biopsy Research Highlights Signal Amplifying Ability and Clear Detection of Cancer Biomarkers

PRESS RELEASE
Leslie Titus Bryant
July 26, 2022

SALT LAKE CITY, UTAH—Spectrum Solutions, LLC today announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry. The project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva. Specifically, amplified EGFR mutations associated with non-small cell lung cancer (NSCLC) using Spectrum’s saliva collection and preservation system with the Electric Field–Induced Release and Measurement (EFRIM) electrostatic platform.

Most lung cancers (85 percent) fall into the category called non-small cell lung cancer (NSCLC). Though this form of lung cancer progresses more slowly than small cell lung cancer (SCLC), 40 percent of those living with NSCLC will have it spread beyond the lungs by the time it is diagnosed. Many advances in targeted treatments for lung cancer are based on the evaluation of three EGFR gene mutations. Current methods for diagnosis and monitoring include invasive tissue biopsies, which create clinical obstacles for ongoing mutation analysis and cancer treatment. The less invasive liquid biopsy options using free-floating cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in solid tumor cancers have quickly become an important part of the screening, diagnosis, and monitoring process for cancer patients.

“The ability to detect EGFR mutations using ctDNA enables a broad range of clinical applications such as the early detection of disease, practical applications of personalized treatments, predicting treatment response, and monitoring resistance,” said Rohit Gupta, Chief Medical Officer for Spectrum Solutions. “Proving it can be done using saliva is groundbreaking.”

The ctDNA associated with NSCLC, termed ‘ultra-short’ ctDNA (usctDNA), is a third smaller in size than the average fragment. This has made it extremely hard to detect using current liquid biopsy technology, especially without additional amplification. Prior to this study, Wong’s team published on the successful detection of the same usctDNA EGFR mutations from both early and late-stage patients living with NSCLC in both blood and saliva. When paired with new technology developed at UCLA by Dr. Wong, known as EFIRM, study findings have demonstrated an impressive 14-fold amplification of detectable usctDNA from saliva collected and stabilized using Spectrum’s SDNA-1000 compared to raw or neat saliva. Additionally, after diluting the signal down to 10 percent of the original concentration, the team continued to see enhanced amplification benefits from the Spectrum device, leading scientists to believe detection of a single ctDNA fragment may now be possible.

“Achieving detectable concentrations of ctDNA in body fluids is not an easy task. The significance of successfully demonstrating this capability with saliva is the holy grail of liquid biopsy research,” said Dr. David Wong, UCLA School of Dentistry. “The discovery delivers, for the first time, a noninvasive opportunity for detection and the ongoing ‘real-time’ understanding of somatic mutation activity to direct and redirect successful treatment strategies.”

“Understanding how many face the likelihood of treatment resistance, it is actually life-changing to know the results from this research collaboration with Dr. Wong and UCLA has real power to positively impact patient outcomes,” said Steve Fanning, CEO of Spectrum Solutions. “For patients, the ability to use the self-collection of saliva empowers a new, safer, easier and pain-free era of detection and treatment innovation with real at-home remote care possibilities.”

Read this release on BusinessWire.com

BIOPRESERVATION AND BIOBANKING JOURNAL-20-03-2022

The BIO Journal is the first journal to provide comprehensive peer-reviewed coverage of biospecimen procurement, processing, preservation, and banking, including ethical, legal, and societal considerations. Publishing every two months, approved submissions awaiting publication can be found in the Ahead of Print section online or by clicking the manuscript ID link below.

Manuscript ID: BIO-2022-0093 – VOLUME 20, ISSUE 4 / AUGUST 2022, Feng Li et al, Proficiency testing of EGFR mutations detection in saliva using Spectrum saliva collector (SDNA-1000) and preservative solution detected by EFIRM.

Read the Case Study “Collaboration Identifies Unique Point-of-Collection Sample Prep Advantages”

Published UCLA and Spectrum Saliva Liquid Biopsy Research Highlights Signal Amplifying Ability and Clear Detection of Cancer Biomarkers

PRESS RELEASE
Leslie Titus Bryant
July 26, 2022

SALT LAKE CITY, UTAH—Spectrum Solutions, LLC today announced the publishing of findings from their research collaboration with the University of California at Los Angeles (UCLA) and Dr. David Wong, UCLA School of Dentistry. The project has successfully demonstrated a superior ability to detect circulating tumor DNA (ctDNA) from saliva. Specifically, amplified EGFR mutations associated with non-small cell lung cancer (NSCLC) using Spectrum’s saliva collection and preservation system with the Electric Field–Induced Release and Measurement (EFRIM) electrostatic platform.

Most lung cancers (85 percent) fall into the category called non-small cell lung cancer (NSCLC). Though this form of lung cancer progresses more slowly than small cell lung cancer (SCLC), 40 percent of those living with NSCLC will have it spread beyond the lungs by the time it is diagnosed. Many advances in targeted treatments for lung cancer are based on the evaluation of three EGFR gene mutations. Current methods for diagnosis and monitoring include invasive tissue biopsies, which create clinical obstacles for ongoing mutation analysis and cancer treatment. The less invasive liquid biopsy options using free-floating cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) in solid tumor cancers have quickly become an important part of the screening, diagnosis, and monitoring process for cancer patients.

“The ability to detect EGFR mutations using ctDNA enables a broad range of clinical applications such as the early detection of disease, practical applications of personalized treatments, predicting treatment response, and monitoring resistance,” said Rohit Gupta, Chief Medical Officer for Spectrum Solutions. “Proving it can be done using saliva is groundbreaking.”

The ctDNA associated with NSCLC, termed ‘ultra-short’ ctDNA (usctDNA), is a third smaller in size than the average fragment. This has made it extremely hard to detect using current liquid biopsy technology, especially without additional amplification. Prior to this study, Wong’s team published on the successful detection of the same usctDNA EGFR mutations from both early and late-stage patients living with NSCLC in both blood and saliva. When paired with new technology developed at UCLA by Dr. Wong, known as EFIRM, study findings have demonstrated an impressive 14-fold amplification of detectable usctDNA from saliva collected and stabilized using Spectrum’s SDNA-1000 compared to raw or neat saliva. Additionally, after diluting the signal down to 10 percent of the original concentration, the team continued to see enhanced amplification benefits from the Spectrum device, leading scientists to believe detection of a single ctDNA fragment may now be possible.

“Achieving detectable concentrations of ctDNA in body fluids is not an easy task. The significance of successfully demonstrating this capability with saliva is the holy grail of liquid biopsy research,” said Dr. David Wong, UCLA School of Dentistry. “The discovery delivers, for the first time, a noninvasive opportunity for detection and the ongoing ‘real-time’ understanding of somatic mutation activity to direct and redirect successful treatment strategies.”

“Understanding how many face the likelihood of treatment resistance, it is actually life-changing to know the results from this research collaboration with Dr. Wong and UCLA has real power to positively impact patient outcomes,” said Steve Fanning, CEO of Spectrum Solutions. “For patients, the ability to use the self-collection of saliva empowers a new, safer, easier and pain-free era of detection and treatment innovation with real at-home remote care possibilities.”

Read this release on BusinessWire.com

BIOPRESERVATION AND BIOBANKING JOURNAL-20-03-2022

The BIO Journal is the first journal to provide comprehensive peer-reviewed coverage of biospecimen procurement, processing, preservation, and banking, including ethical, legal, and societal considerations. Publishing every two months, approved submissions awaiting publication can be found in the Ahead of Print section online or by clicking the manuscript ID link below.

Manuscript ID: BIO-2022-0093 – VOLUME 20, ISSUE 4 / AUGUST 2022, Feng Li et al, Proficiency testing of EGFR mutations detection in saliva using Spectrum saliva collector (SDNA-1000) and preservative solution detected by EFIRM.

Read the Case Study “Collaboration Identifies Unique Point-of-Collection Sample Prep Advantages”

Noninvasive
Saliva Diagnostics

This changes everything

Health is a dynamic state of well-being. Healthcare providers and researchers have long believed that changes in our saliva record our ongoing state-of-health story. Interestingly, saliva acts as a wide resource of genomic information useful for identifying and monitoring in real-time a disease as well as its state of progression. Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant.

Spectrum’s technically-superior saliva collection systems have not only been engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications but deliver the safest, most robust biomaterial for the earliest detection and diagnosis of disease and infection.

  • Saliva provides the earliest path to critical detection and diagnosis
  • Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
  • First EUA authorized saliva collection device for COVID-19 testing & authorized device for direct-to-patient at-home sample self-collection
  • Used in supervised & unsupervised sample collection LDT workflows of symptomatic & asymptomatic users
  • Pain-free, non-invasive, & safe – ideal for those needing frequent & repeat testing
  • In-device live virus inactivation at ambient temps (COVID-19 EUA validated data)
  • Eliminates hooded containment of samples arriving at the testing lab
  • No temperature-controlled storage or transport of collected saliva samples
  • Single device for DNA & viral RNA applications
  • Safest collection approach & most robust biomaterial for detecting COVID-19
  • Delivers 99.998% highest levels of testing accuracy & sensitivity
  • Formulation identifies infections at its earliest stage from as few as 200 copies/ml (lateral flow rapid tests need 10,000-20,000 copies/ml)
  • A single preserved saliva sample provides opportunity for multiple tests
  • Over two weeks of post-collection stability with no degradation in sample efficacy
  • System maintains critical bio-sample consistency
  • Mass-testing scalability & easy device integration using validated and supported processes
  • Mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
  • Eliminates UN3373 shipping designation with clearance from USPS, FedEx, & UPS
  • Delivers the highest levels of testing accuracy using qualified extraction chemistries
Questions, Let’s Connect!

Noninvasive
Saliva Diagnostics

This changes everything

Health is a dynamic state of well-being. Healthcare providers and researchers have long believed that changes in our saliva record our ongoing state-of-health story. Interestingly, saliva acts as a wide resource of genomic information useful for identifying and monitoring in real-time a disease as well as its state of progression. Saliva analysis looks at the cellular level, the biologically active compounds, making it a true representative of what is clinically relevant.

Spectrum’s technically-superior saliva collection systems have not only been engineered to lead the saliva collection industry in molecular diagnostics and clinical research applications but deliver the safest, most robust biomaterial for the earliest detection and diagnosis of disease and infection.

  • Saliva provides the earliest path to critical detection and diagnosis
  • Saliva contains the entire library of proteins, hormones, antibodies, and other molecular compounds measured in routine blood tests
  • First EUA authorized saliva collection device for COVID-19 testing & authorized device for direct-to-patient at-home sample self-collection
  • Used in supervised & unsupervised sample collection LDT workflows of symptomatic & asymptomatic users
  • Pain-free, non-invasive, & safe – ideal for those needing frequent & repeat testing
  • In-device live virus inactivation at ambient temps (COVID-19 EUA validated data)
  • Eliminates hooded containment of samples arriving at the testing lab
  • No temperature-controlled storage or transport of collected saliva samples
  • Single device for DNA & viral RNA applications
  • Safest collection approach & most robust biomaterial for detecting COVID-19
  • Delivers 99.998% highest levels of testing accuracy & sensitivity
  • Formulation identifies infections at its earliest stage from as few as 200 copies/ml (lateral flow rapid tests need 10,000-20,000 copies/ml)
  • A single preserved saliva sample provides opportunity for multiple tests
  • Over two weeks of post-collection stability with no degradation in sample efficacy
  • System maintains critical bio-sample consistency
  • Mass-testing scalability & easy device integration using validated and supported processes
  • Mitigates any risk of infection throughout the testing process
  • Pinpoint life-cycle stage of active viral infection
  • Eliminates UN3373 shipping designation with clearance from USPS, FedEx, & UPS
  • Delivers the highest levels of testing accuracy using qualified extraction chemistries
Questions, Let’s Connect!
Major League Baseball Logo

Bringing Baseball Back!

How you collect saliva makes a big
diagnostic difference

Increase workplace safety and build team confidence with simple and safe repeat testing programs supporting 100% accurate early detection and easy direct-to-user at-home options. Just ask the MLB, real-world, mass testing scenarios require an authorized, proven, and supported system that mitigates any risk of exposure. See how our saliva collection system is credited for bringing baseball back” and making Salt Lake “the league’s most important city”.

™/© 2020 MLB

Case Study
Major League Baseball Logo

Bringing Baseball Back!

How you collect saliva makes a big
diagnostic difference

Increase workplace safety and build team confidence with simple and safe repeat testing programs supporting 100% accurate early detection and easy direct-to-user at-home options. Just ask the MLB, real-world, mass testing scenarios require an authorized, proven, and supported system that mitigates any risk of exposure. See how our saliva collection system is credited for bringing baseball back” and making Salt Lake “the league’s most important city”.

™/© 2020 MLB

Case Study

Why Spectrum?

Headquartered in Salt Lake City, Utah, Spectrum Solutions is a laboratory medicine life science company using its focused industry expertise to drive noninvasive molecular diagnostic and screening IVD innovation. Our pioneering research, products, engineering, and development-to-delivery test kit commercialization capabilities are setting new standards of modernized care for patients, providers, and laboratories in the testing, managing, and treatment of disease.

We believe when you bridge the gap between science and real direct-to-patient medical solutions you deliver innovation with the practical power to impact and change outcomes. Learn more about our expertise by visiting our three fully integrated division pages: Spectrum Medical Science SM, Spectrum Compounding Pharmacy TM, and Spectrum Clinical Manufacturing SM.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Head of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Why Spectrum?

Headquartered in Salt Lake City, Utah, Spectrum Solutions is a laboratory medicine life science company using its focused industry expertise to drive noninvasive molecular diagnostic and screening IVD innovation. Our pioneering research, products, engineering, and development-to-delivery test kit commercialization capabilities are setting new standards of modernized care for patients, providers, and laboratories in the testing, managing, and treatment of disease.

We believe when you bridge the gap between science and real direct-to-patient medical solutions you deliver innovation with the practical power to impact and change outcomes. Learn more about our expertise by visiting our three fully integrated division pages: Spectrum Medical Science SM, Spectrum Compounding Pharmacy TM, and Spectrum Clinical Manufacturing SM.

#partoftheSolution

Leslie Titus Bryant Spectrum Solutions SpokesmanSpectrum Corporate Spokesman
Leslie Titus Bryant
Head of Marketing & Brand
admin@spectrumsolution.com

Tim Rush Public Relations, Springboard 5Media Contact
Tim Rush, Springboard5
801-208-1100
tim.rush@springboard5.com

Can we answer any questions?

Let's Connect

Contact Us

#SpitMatters

Can we answer any questions?

Let's Connect

Contact Us

#SpitMatters

Outside-of-the-Box Thinking, Inside-of-the-Box Clinical Innovation

Anywhere from customized testing solutions to new medical science product innovations–we’re here to help.

Outside-of-the-Box Thinking, Inside-of-the-Box Innovation

Anywhere from customized testing solutions to new medical science product innovations–we’re here to help.

2022-07-25T22:26:52+00:00
Go to Top